TX-FLUENCE
9.5.2022 14:02:07 CEST | Business Wire | Press release
Fluence , a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced its sponsorship of Wageningen University & Research’s (WUR) third Autonomous Greenhouse Challenge in the Netherlands. For the first time in the challenge’s history, WUR leveraged a broad-spectrum LED-only lighting system—specifically Fluence’s VYPR 3p solution—instead of high-pressure sodium (HPS) fixtures. WUR also implemented Fluence’s innovative lighting control solution, Wireless Flex Dimming, into the facility.
Wageningen University & Research is dedicated to researching the future of agriculture by exploring autonomous greenhouse technology, climate control, crop modeling, advanced sensors, data intelligence, computer vision and robotics. Beginning in June 2021, WUR organized its third Autonomous Greenhouse Challenge to task different international teams with sustainably growing vegetables in a fully automated greenhouse environment.
“We expect that food production in greenhouse horticulture can be further improved by adding more artificial intelligence to the agricultural industry,” said Silke Hemming, who leads the scientific research team for greenhouse technology at WUR, in a statement . “We make connections with international partners through this unique challenge, so that we can take major steps.”
One of the challenges growers face when transitioning from HPS to LED luminaires is that a typical HPS system is limited in its dimming capabilities, unlike LED technology. By leveraging state-of-the-art, qualified Bluetooth mesh technology enabled by Technology Partner SILVAIR, Fluence’s Wireless Flex Dimming solution allows growers to have precise control of dim light levels. By connecting the VYPR top light fixtures to the climate computer through Wireless Flex Dimming, the participants were empowered to implement advanced lighting control strategies that maximized plant growth and quality.
“In any greenhouse or controlled environment, the reliability of a cultivation system is paramount,” said Theo Tekstra, Fluence’s technical director for Europe, Middle East and Africa. “Wireless Flex Dimming enables growers to simplify installation and gain solid wireless control of their light levels, whether in an autonomous scientific experiment or a large-scale greenhouse. We are now implementing this technology for customers with more than 7,000 connected fixtures.”
WUR’s Autonomous Greenhouse Challenge also seeks to discover how artificial intelligence can play a role in the future of cultivation, including how to reduce energy input and cost.
“The complete cultivation process is handled by AI and algorithms developed by the teams,” Tekstra added. “One important input factor is the strong fluctuations in high energy prices. Fluence’s Wireless Flex Dimming integration with the Ridder climate computer allows the teams to modulate the lights within their lighting strategy algorithms to optimize energy costs. Fluence’s mission is to help the world grow smarter—something these incredible teams are tackling head-on. We are delighted to support WUR and this initiative with our advanced lighting solutions.”
Fluence continues to demonstrate how secure, intelligent lighting solutions based on the latest technology innovations can add value to the global horticulture industry. The Wireless Flex Dimming Receiver has been awarded PSA Certified™ Level 1 (an independent measurement of security best practices spearheaded by Arm) from Riscure. PSA Certified is recognized by the DesignLights Consortium as an approved cybersecurity standard for networked lighting control systems.
Results from the challenge will be published in July 2022. To follow the competing teams’ progress, visit WUR’s greenhouse challenge dashboard here . For more information on Fluence and its portfolio of controls and luminaires, visit www.fluence.science .
About Fluence
Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220509005233/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
